Over the past two decades, several global health institutions have attempted to improve public health by influencing the characteristics of health product markets, including pricing, quality, overall production, and the supplier and product landscapes. We examine the role of Gavi, the Vaccine Alliance in market shaping.
CGD Policy Blogs
Effective procurement of health products—medicines, diagnostics, and devices—is a foundational function for any health system and essential for progress toward the health-related Sustainable Development Goals.
To achieve universal health coverage and provide their citizens with access to quality and affordable medicines, countries will need to buy these lifesaving products efficiently and effectively.
Since Monday, leading health officials from around the world have been meeting in Geneva, Switzerland for the 72nd World Health Assembly.
In March, our team at the Center for Global Development and Office of Health Economics posted a consultation draft of a policy proposal for a Market-Driven, Value-Based Advanced Commitment (MVAC). The MVAC is a new mechanism that puts middle-income country governments in the driver’s seat to accelerate R&D for diseases that affect the world’s poor—specifically, the 10 million men, women, and children who develop tuberculosis (TB) disease each year and desperately need better therapies.
Innovation is a critical tool in the global fight against disease—especially for tuberculosis (TB), an infectious disease that primarily affects the poor and vulnerable and ranks among the top 10 causes of death in the world.